Valuation dashboard for Precigen, Inc. (PGEN) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies.
Analysis Summary
Precigen, Inc. reported revenue of $9.7M in the most recent fiscal year, growing at a 5-year CAGR of -21.3%.
Balance sheet quality for PGEN: current ratio of 3.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Models
| DCF Fair Value | $-0.62 |
| vs Current Price | -108.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PGEN | Precigen, Inc. | $2.7B | |||
| TERN | Terns Pharmaceuticals, Inc. | $4.8B | 4.90 | -20.0% | |
| DNTH | Dianthus Therapeutics, Inc. | $5.7B | 4.93 | -32.9% | |
| ELVN | Enliven Therapeutics, Inc. | $3.5B | |||
| RLAY | Relay Therapeutics, Inc. | $4.1B | 4.29 | -48.8% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.6B |
Price
| Price | $7.43 |
| Market Cap | $2.7B |
| Exchange | NASDAQ |
| Country | US |
Related companies: AMLX · DNTH · ELVN · IMTX · NKTR · ORIC · RLAY
Explore sector: Healthcare · Biotechnology
More sections of PGEN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks